X4 Pharmaceuticals Files 8-K on Exit Activities

TL;DR

X4 Pharma filed an 8-K today, looks like they're cleaning house with some exit/disposal activities.

AI Summary

On February 6, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates activities related to cost associated with exit or disposal activities, Regulation FD disclosure, and financial statements and exhibits. The company, formerly known as Arsanis, Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.

Why It Matters

This 8-K filing signals potential restructuring or divestiture activities within X4 Pharmaceuticals, which could impact its future operations and strategic direction.

Risk Assessment

Risk Level: medium — Filings related to exit or disposal activities can indicate financial distress or strategic shifts that carry inherent business risks.

Key Numbers

• 001-38295 — SEC File Number (Identifies the company's filing history with the SEC.)
• 27-3181608 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• X4 Pharmaceuticals, Inc. (company) — Registrant
• Arsanis, Inc. (company) — Former company name
• February 6, 2025 (date) — Date of report
• Boston, Massachusetts (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market
• $3.0 million — it will incur charges of approximately $3.0 million for severance and other employee termin
• $30 — turing will decrease annual spending by $30-35 million and believes it will have su

Filing Documents

• xfor-20250206.htm (8-K) — 35KB
• exhibit991feb62025.htm (EX-99.1) — 15KB
• image_0.jpg (GRAPHIC) — 13KB
• 0001628280-25-004254.txt ( ) — 201KB
• xfor-20250206.xsd (EX-101.SCH) — 2KB
• xfor-20250206_lab.xml (EX-101.LAB) — 23KB
• xfor-20250206_pre.xml (EX-101.PRE) — 13KB
• xfor-20250206_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On February 6, 2025, X4 Pharmaceuticals, Inc. (the "Company" or "X4") announced a strategic restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat those with chronic neutropenia, while also optimizing its U.S. promotion of XOLREMDI. In connection with this shift in operational focus and strategic restructuring, the Company expects to implement a net reduction of its employee headcount by 43 employees, or approximately 30% of the Company's employees. The strategic restructuring activities include (i) discontinuing of research efforts, (ii) closing the Company's facility in Vienna, Austria, (iii) pausing pre-clinical drug candidate programs, (iv) scaling the U.S. commercial field team and supporting roles across the Company and (v) streamlining other spending to support the ongoing clinical development of mavorixafor for the larger population of those with chronic neutropenia. The Company estimates that the workforce reduction will be substantially completed in the first quarter of 2025. The Company estimates that it will incur charges of approximately $3.0 million for severance and other employee termination-related costs, primarily in the first quarter of 2025. The Company expects the shift in operational focus and strategic restructuring will decrease annual spending by $30-35 million and believes it will have sufficient funds to support operations into the first half of 2026. The estimate of costs that the Company expects to incur related to the strategic restructuring as well as the decrease in annual spending, and the timing thereof are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the actions described above.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 6, 2025, the Company issued a press release titled "X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia," a copy of which is attached hereto as Exhibit 99.1. The information under this Item 7.01, including Exhibit 99.1 hereto, are being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

Forward-Looking Statements This Form 8-K contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the initiation, timing, progress, and results of our current and future preclinical studies and clinical trials and related preparatory work and the period during which the results of the trials will become available, as well as our research and development programs; and the mission and goals for our business. Any forward-looking statements in this Form 8-K are based on management's current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: X4's restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; X4's future financial performance and position, business strategy, and plans and objectives for future operations; the timing, execution, and expected impact of X4's restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; X4's commercial plans and strategy for mavorixafor; the expected sufficiency of X4's existing cash resources; the internal and external costs required for X4's ongoing and planned activities, and the resulting impact on

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated February 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: February 6, 2025 By: /s/ Adam S. Mostafa Name: Adam S. Mostafa Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR